We speculated RBL2-mediated repression of AURKA/B pathway genes could improve outcome in p53 WT NSCLC patients by increasing cancer cell and tumor sensitivity to NSCLC therapy agents. This evidence concerns the gene RBL2 and non-small cell lung carcinoma.